In 2009 the influenza A (H1N1) pandemic struck the United States and, according to CDC estimates, affected approximate 60.8 million people with 274,304 hospitalisations, and 12,469 deaths. While this strain of the flu virus continues to circulate worldwide, the rapid and significant impact of this pandemic revealed the need to find ways to speed response to future events. One area of opportunity is the sterility test. Anna Mills, Senior Validation Specialist at Rapid Micro Biosystems, deals with accelerating and automating sterility testing in microbial quality control.
https://international-pharma.com/wp-content/uploads/2015/06/Accelerating…pdf.pdf